

- **Name:** Samuel Cytryn
 - **Current Position & Affiliation:** Assistant Attending, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
 - **Country:** USA
-

- **Educational Background:**

Medical School: Icahn School of Medicine at Mount Sinai

Internal Medicine Residency: New York University (Chief Resident)

Medical Oncology Fellowship: Memorial Sloan Kettering Cancer Center (Chief Fellow)

- **Professional Experience:**

Assistant Attending, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center

- **Professional Organizations:**

American Society of Clinical Oncology

European Society of Medical Oncology

- **Main Scientific Publications:**

Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. *Lancet Oncol.* 2023 Oct;24(10):1073-1082. doi: 10.1016/S1470-2045(23)00358-3. Epub 2023 Sep 1. PMID: 37666264; PMCID: PMC11208000.

Cytryn SL, Pandit-Taskar N, Lumish MA, Maron SB, Gu P, Ku GY, Chou JF, Capanu M, Antoine A, Loegel D, Feder L, Philemond S, Lyashchenko SK, Lewis JS, Paroder V, Srivastava A, Tang LH, Schoder H, Janjigian YY. ¹⁸F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. *J Nucl Med.* 2024 May 1;65(5):722-727. doi: 10.2967/jnumed.123.267186. PMID: 38514081; PMCID: PMC11064823.

Cytryn SL, Janjigian YY. HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers. *J Natl Compr Canc Netw.* 2023 Apr;21(4):423-429. doi: 10.6004/jnccn.2023.7010. PMID: 37015333.

Klempner SJ, Cowden ES, **Cytryn SL**, Fassan M, Kawakami H, Shimada H, Tang LH, Wagner DC, Yatabe Y, Savchenko A, Salcius J, Johng D, Chen J, Montenegro G, Moehler M. PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays. *JCO Precis Oncol.* 2024 Jun;8:e2400230. doi: 10.1200/PO.24.00230. PMID: 38822761.

Fick CN, Dunne EG, Sihag S, Molena D, **Cytryn SL**, Janjigian YY, Wu AJ, Worrell SG, Hofstetter WL, Jones DR, Gray KD. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma. *Ann Thorac Surg.* 2024 Jul;118(1):130-140. doi: 10.1016/j.athoracsur.2024.02.021. Epub 2024 Feb 24. PMID: 38408631; PMCID: PMC11194153.